Adjuvant radioactive iodine therapy is widely used to treat well-differentiated thyroid carcinoma (WDTC), but is known to result in radiation absorption by the testes, the long-term effects of which are unknown. To determine the effects of radioactive iodine on testis function and fertility in men with WDTC, Sawka et al. conducted a systematic review of controlled studies of radioiodine therapy in such patients.
Longitudinal studies of the effect of a single dose of ≤150 mCi (5.56 GBq) of radioiodine showed that serum levels of luteinizing hormone and follicle-stimulating hormone (FSH) peaked 2–6 months after radioiodine administration, and normalized in the majority of patients by 12–18 months. However, repeated or high cumulative radioiodine activities were associated with a greater risk of abnormalities. In one study, the majority of men who received >594 mCi (22 GBq) radioiodine had elevated FSH at 18 months. One 12-month study found a persistent reduction in sperm count in 7 of 53 patients; the cumulative dose of radioiodine correlated positively with FSH level, and inversely with sperm count. Another study with a mean follow-up >7 years found a positive correlation between radioiodine dose and FSH level. Radioiodine treatment was not found to affect rates of infertility, pregnancy loss or congenital malformation; however, sample sizes in these studies were small and the outcomes self-reported.
The authors recommend that sperm banking be offered to men if multiple doses of radioiodine are planned (particularly if single doses exceed 150 mCi), if the cumulative planned dose is >350 mCi (13 GBq), or if they are attempting conception within 18 months of therapy.
Rights and permissions
About this article
Cite this article
Radioiodine in thyroid cancer—effects on testicular function. Nat Rev Endocrinol 4, 124 (2008). https://doi.org/10.1038/ncpendmet0741
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0741